2025
Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2020
Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial.
El Khoudary SR, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman M, Naftolin F, Hodis H, Brinton E, Miller V, Taylor H, Budoff M. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial. Menopause The Journal Of The North American Menopause Society 2020, 27: 255-262. PMID: 32015261, PMCID: PMC7113029, DOI: 10.1097/gme.0000000000001472.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessEpicardial adipose tissueProgression of atherosclerosisCIMT progressionHormone therapyAtherosclerosis progressionMenopausal womenOral conjugated equine estrogenParacardial adipose tissue volumeMenopausal hormone therapyPlacebo-controlled trialConjugated equine estrogensFat depositionIntima-media thicknessMcg/dAdipose tissue volumeRoute of administrationPAT changesCEE administrationPlacebo groupEquine estrogensT-E2Fat accumulationMonth progressionO-CEE
2017
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesteroneLongitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo
Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo. Menopause The Journal Of The North American Menopause Society 2017, 24: 238-246. PMID: 27779568, PMCID: PMC5323337, DOI: 10.1097/gme.0000000000000756.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAutonomic Nervous System DiseasesDrug Therapy, CombinationEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHot FlashesHumansIrritable MoodLongitudinal StudiesMiddle AgedPostmenopauseProgesteroneProgestinsSleep Initiation and Maintenance DisordersTreatment OutcomeVasomotor SystemConceptsOral conjugated estrogensActive treatment armsBody mass indexTreatment armsRace/ethnicityMonths postrandomizationNight sweatsPostmenopausal womenHot flashesMass indexMenopausal symptomsConjugated estrogensEarly postmenopausal womenMenopausal hormone therapyFinal menstrual periodProportion of womenHormone regimensTransdermal estradiolTransdermal estrogenHormone therapyVasomotor symptomsSymptom reliefTreat analysisActive treatmentConventional doses
2015
Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study
Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLOS Medicine 2015, 12: e1001833. PMID: 26035291, PMCID: PMC4452757, DOI: 10.1371/journal.pmed.1001833.Peer-Reviewed Original ResearchConceptsCognitive outcomesMood outcomesVerbal learning/memoryAttention/executive functionEffect sizeAuditory attention/Kronos Early Estrogen Prevention StudyAffective studiesLearning/memoryModified Mini-Mental State ExaminationMenopausal hormone therapyMedium effect sizeMini-Mental State ExaminationTreatment-related benefitsAttention/Cognitive factorsMental flexibilityExecutive functionMood measuresMood effectsAnxiety symptomsAge 65 y.Beneficial mood effectsCognitive AssessmentMood states
2014
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.
Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals Of Internal Medicine 2014, 161: 249-60. PMID: 25069991, DOI: 10.7326/m14-0353.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultC-Reactive ProteinCarotid Intima-Media ThicknessCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHumansInsulin ResistanceLipidsMiddle AgedPostmenopauseProgesteroneRadiographyRisk FactorsSex Hormone-Binding GlobulinConceptsCarotid artery intima-media thicknessMenopausal hormone therapyCoronary artery calciumCVD riskMenopausal womenRisk factorsCardiovascular diseaseT-E2O-CEEHigh-density lipoprotein cholesterol levelsOral conjugated equine estrogenArtery intima-media thicknessEnd pointSex hormone-binding globulinCardiovascular risk factorsCVD risk factorsLipid-Lowering TherapyPrimary end pointSecondary end pointsSerious adverse eventsConjugated equine estrogensLipoprotein cholesterol levelsC-reactive proteinIntima-media thicknessHealthy menopausal womenCurrent and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy for Menopausal Women
Santen RJ, Kagan R, Altomare CJ, Komm B, Mirkin S, Taylor HS. Current and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy for Menopausal Women. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 733-747. PMID: 24423357, DOI: 10.1210/jc.2013-3680.Peer-Reviewed Original ResearchConceptsTissue selective estrogen complexSelective ER modulatorsPostmenopausal womenEstrogen deficiencyMenopausal womenAvailable estrogen receptorRelevant English-language articlesHysterectomized postmenopausal womenLarge observational studiesReceptor-based therapiesEnglish-language articlesPossible adverse effectsOptimal therapeutic profileProgestogen useSystemic estrogenHormonal therapyHormone therapyTherapeutic guidelinesMenopausal symptomsEstrogen complexObservational studyDifferent therapiesEstrogen receptorER agonismIndividualized approach
2013
Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance
Dowling NM, Gleason CE, Manson JE, Hodis HN, Miller VM, Brinton EA, Neal-Perry G, Santoro MN, Cedars M, Lobo R, Merriam GR, Wharton W, Naftolin F, Taylor H, Harman SM, Asthana S. Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance. PLOS ONE 2013, 8: e68741. PMID: 23874743, PMCID: PMC3714288, DOI: 10.1371/journal.pone.0068741.Peer-Reviewed Original ResearchMeSH KeywordsApolipoproteins EArtificial IntelligenceCognitionFemaleGenotypeHumansMiddle AgedPostmenopauseVascular DiseasesConceptsKronos Early Estrogen Prevention StudyLow-risk classPostmenopausal womenCV risk factor profileDisease riskApolipoprotein E (APOE) ε4 alleleCV risk classificationCV risk profileHigh-risk womenRisk factor profileCV disease riskVascular disease riskLast menstrual periodConsiderable interindividual variabilityEducation levelHigh-risk classCV diseaseCV riskCardiovascular riskMenopausal womenMenstrual periodPrevention StudyPreclinical diseasePreventive strategiesTreatment decisionsEctopic fat and adipokines in metabolically benign overweight/obese women: The kronos early estrogen prevention study
Ogorodnikova AD, Khan UI, McGinn AP, Zeb I, Budoff MJ, Harman SM, Miller VM, Brinton EA, Manson JE, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Ectopic fat and adipokines in metabolically benign overweight/obese women: The kronos early estrogen prevention study. Obesity 2013, 21: 1726-1733. PMID: 23670850, PMCID: PMC3748250, DOI: 10.1002/oby.20200.Peer-Reviewed Original ResearchConceptsEctopic fatHepatic fatTop tertilePrevention StudyBottom tertileEpicardial fatKronos Early Estrogen Prevention StudyOverweight/obese womenOverweight/obese individualsCardiometabolic risk profileNormal-weight womenHMW adiponectin levelsOverweight/obeseNormal-weight individualsCross-sectional analysisObese womenWeight womenAdiponectin levelsMetabolic syndromeHMW adiponectinObese individualsWeight individualsPericardial fatCardiovascular diseaseHigher odds
2012
Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS study
Huang G, Wang D, Khan UI, Zeb I, Manson JE, Miller V, Hodis HN, Budoff MJ, Merriam GR, Harman MS, Brinton EA, Cedars MI, Su Y, Lobo RA, Naftolin F, Santoro N, Taylor HS, Wildman RP. Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS study. Cardiovascular Diabetology 2012, 11: 52. PMID: 22587616, PMCID: PMC3461442, DOI: 10.1186/1475-2840-11-52.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtherosclerosisBiomarkersBlood GlucoseBlood PressureC-Reactive ProteinCarotid Intima-Media ThicknessCoronary DiseaseCross-Sectional StudiesDouble-Blind MethodFemaleHormone Replacement TherapyHumansInsulinLife StyleLipidsMiddle AgedObesityPostmenopauseRadiographyRetinol-Binding Proteins, PlasmaRisk FactorsConceptsRetinol-binding protein 4Carotid artery intima-media thicknessCoronary artery calcificationCardiometabolic risk factorsRBP4 levelsHigher RBP4 levelsRisk factorsPostmenopausal womenCross-sectional analysisSubclinical atherosclerosisKronos Early Estrogen Prevention StudyArtery intima-media thicknessSubclinical coronary atherosclerosisResultsThe mean ageSerum RBP4 levelsProtein 4C-reactive proteinIntima-media thicknessAdditional risk factorsWestern blot analysisArtery calcificationCIMT levelsCoronary atherosclerosisBlood pressureHigh triglyceridesUsing bazedoxifene plus conjugated estrogens for treating postmenopausal women
Taylor HS, Ohleth K. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women. Menopause The Journal Of The North American Menopause Society 2012, 19: 479-485. PMID: 22278343, DOI: 10.1097/gme.0b013e31823dbbca.Peer-Reviewed Original ResearchConceptsBZA/CETissue selective estrogenConjugated estrogensPostmenopausal womenBone massSelective estrogenVulvar-vaginal atrophyPlacebo-controlled studyHot flush frequencyLevel I evidenceAmenorrhea ratesEndometrial hyperplasiaEndometrial stimulationHot flushesClinical outcomesClinical efficacyI evidenceFlush frequencySafety outcomesEstrogenPlaceboBazedoxifeneWomenOverall safetyUnexpected finding
2011
Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS)
Huang G, Wang D, Zeb I, Budoff MJ, Harman SM, Miller V, Brinton EA, Khoudary S, Manson JE, Sowers MR, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2011, 221: 198-205. PMID: 22209479, PMCID: PMC3288598, DOI: 10.1016/j.atherosclerosis.2011.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAdiposityAdultAge FactorsAsymptomatic DiseasesBiomarkersBody Mass IndexC-Reactive ProteinCoronary Artery DiseaseDouble-Blind MethodEstrogen Replacement TherapyFemaleHumansInsulinLinear ModelsLiverLogistic ModelsMetabolic SyndromeMiddle AgedMultivariate AnalysisOdds RatioPericardiumPostmenopauseProspective StudiesRisk AssessmentRisk FactorsTomography, X-Ray ComputedUnited StatesVascular CalcificationWaist CircumferenceConceptsKronos Early Estrogen Prevention StudyCoronary artery calcificationIntra-hepatic fatCVD risk markersThoracic fatHs-CRPPrevention StudyRisk markersRisk factorsCardiac fatCardiovascular disease risk factorsCardiometabolic risk factorsDisease risk factorsSubclinical cardiovascular diseaseSubclinical atherosclerosis burdenThoracic adipose tissueAtherosclerosis burdenMultivariable adjustmentArtery calcificationCVD riskPostmenopausal womenSubclinical atherosclerosisMenopausal womenHepatic fatAdiposity measuresTiming and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes
Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes. The American Journal Of Medicine 2011, 124: 199-205. PMID: 21396500, PMCID: PMC3107840, DOI: 10.1016/j.amjmed.2010.09.021.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCardiovascular SystemCoronary DiseaseDrug Administration ScheduleEstrogen Replacement TherapyEstrogensFemaleHumansMiddle AgedPostmenopausePrecision MedicineProgestinsRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsThromboembolismTime FactorsWomen's HealthConceptsMenopausal hormone treatmentCoronary heart disease riskHeart disease riskHormone treatmentExcess coronary heart disease riskWomen's Health Initiative hormone trialsDisease riskBeneficial effectsEstrogen-alone trialCoronary heart diseaseYears of treatmentNet harmTreatment-related risksRoute of administrationCurrent FoodShort durationDrug Administration recommendationsDisease incidence ratesWHI dataWHI estrogenWHI findingsCardiovascular outcomesProgestin trialMenopausal symptomsRisk ratio
2010
Skin wrinkles and rigidity in early postmenopausal women vary by race/ethnicity: baseline characteristics of the skin ancillary study of the KEEPS trial
Wolff E, Pal L, Altun T, Madankumar R, Freeman R, Amin H, Harman M, Santoro N, Taylor HS. Skin wrinkles and rigidity in early postmenopausal women vary by race/ethnicity: baseline characteristics of the skin ancillary study of the KEEPS trial. Fertility And Sterility 2010, 95: 658-662.e3. PMID: 20971461, PMCID: PMC3026089, DOI: 10.1016/j.fertnstert.2010.09.025.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyEarly menopausal womenBody mass indexMenopausal womenHormone therapySkin wrinklesEffects of HTLowest wrinkle scoresEarly postmenopausal womenSkin wrinklingUniversity Medical CenterSignificant racial differencesSkin characteristicsRace/ethnic groupsSkin rigidityRace/ethnicityMenopausal participantsBaseline characteristicsPostmenopausal womenMulticenter trialMass indexPrevention StudyAncillary studiesMedical CenterStudy group
2009
Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman
Sasson IE, Taylor HS. Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman. Fertility And Sterility 2009, 92: 1170.e1-1170.e4. PMID: 19591983, PMCID: PMC2742473, DOI: 10.1016/j.fertnstert.2009.05.071.Peer-Reviewed Original ResearchConceptsPostmenopausal womenEstradiol levelsAromatase inhibitorsAbdominal wallAbdominal wall endometriomaPost-menopausal patientsPost-menopausal womenUnusual clinical presentationAcademic medical centerSource of estrogenRecurrent abdominal wallEndometriotic implantsMedical therapyClinical presentationCyst aspirationCase reportSonographic demonstrationAromatase activityMedical CenterMAIN OUTCOMEWomenPatientsEstrogenSerumInhibitors
2007
Individual dose response of insulin resistance to estrogen therapy.
Jovanovic K, Taylor HS. Individual dose response of insulin resistance to estrogen therapy. The Journal Of Reproductive Medicine 2007, 52: 667-9. PMID: 17879825.Peer-Reviewed Original ResearchConceptsConjugated equine estrogensQuantitative insulin sensitivity check indexInsulin resistanceGlucose/insulin ratioDose responseInsulin sensitivity check indexIndividual dose responsesDoses of estrogenSubjects meeting inclusion criteriaMonths of treatmentMeeting inclusion criteriaEstrogen therapySerum insulinEquine estrogensInsulin ratioCheck indexInclusion criteriaIndividual patientsGlucose levelsEstrogenRandom orderMonthsSignificant changesFirst studySingle subject
2005
Long-term effects of hormone therapy on skin rigidity and wrinkles
Wolff EF, Narayan D, Taylor HS. Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertility And Sterility 2005, 84: 285-288. PMID: 16084862, DOI: 10.1016/j.fertnstert.2004.12.062.Peer-Reviewed Original ResearchConceptsHormone therapyHT usersLong-term hormone therapyAcademic medical centerSkin rigidityCross-sectional analysisWrinkle scoreHormone usersCosmetic benefitsInclusion criteriaLong-term effectsMedical CenterSun exposureTobacco useMAIN OUTCOMENonhormone usersSunscreen useSkin typeTherapyPlastic surgeonsWomenLemperle scaleFacial locationCheekVisual assessment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply